hK5 and hK7, two serine proteinases abundant in human skin, are inhibited by LEKTI domain 6

• DOI: 10.1111/j.1365-2133.2005.06834.x
• Publication Date: 2005-08-19T00:01:56Z
• Authors: T. Egelrud; M. Brattsand; P. Kreutzmann; M. Walden; K. Vitzithum; U.C. Marx; W.G. Forssmann; H.J. Magert
• Keywords: 0303 health sciences; Serine Proteinase Inhibitors; Dose-Response Relationship, Drug; Serine Endopeptidases; Proteinase Inhibitory Proteins, Secretory; In Vitro Techniques; Skin Diseases; 3. Good health; 03 medical and health sciences; Humans; Serine Peptidase Inhibitor Kazal-Type 5; Kallikreins; Fibrinolysin; Carrier Proteins; Skin

Several skin diseases and atopic disorders including Netherton syndrome dermatitis have been associated with mutations deviations of expression SPINK5, the gene encoding human 15-domain serine proteinase inhibitor LEKTI. The biochemical mechanisms underlying this phenomenon not yet fully clarified.To identify target proteinases LEKTI important for processes desquamation inflammation which will enable development specific drugs.The inhibitory activities domains 6 15 were tested on a number commercially available also purified kallikreins hK5 hK7. In addition, recombinant was used.LEKTI domain is potent hK7, whereas exhibits activity plasmin. hK7 in particular are relevant to disorders.The inhibition by indicates an regulatory role inflammation, may explain severe pathological symptoms abnormalities SPINK5 and/or its expression. Thus, represents potential drug treatment these disorders.